Swedish Orphan Biovitrum AB (OSTO:SOBI) Price-to-Tangible-Book : (As of Apr. 27, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Price-to-Tangible-Book?

As of today (2024-04-27), Swedish Orphan Biovitrum AB's share price is kr281.00. Swedish Orphan Biovitrum AB's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was kr-74.28. Hence, Swedish Orphan Biovitrum AB's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Swedish Orphan Biovitrum AB's highest Price to Tangible Book Ratio was 118.40. The lowest was 32.67. And the median was 59.68.

OSTO:SOBI's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.34
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Swedish Orphan Biovitrum AB's share price is kr281.00. Swedish Orphan Biovitrum AB's Book Value per Sharefor the quarter that ended in Mar. 2024 was kr105.59. Hence, Swedish Orphan Biovitrum AB's P/B Ratio of today is 2.66.

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Swedish Orphan Biovitrum AB's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Tangible-Book falls into.

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Calculation

Swedish Orphan Biovitrum AB's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	281.00	/	-74.282
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Swedish Orphan Biovitrum AB Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (OSTO:SOBI) Headlines

No Headlines